TdT+ T-Lymphoblastic Proliferation in Castleman Disease

Chang Gok Woo; Jooryung Huh

doi:10.4132/jptm.2014.11.17

Articles

Page Path: HOME > J Pathol Transl Med > Volume 49(1); 2015 > Article

Letter to the editor TdT+ T-Lymphoblastic Proliferation in Castleman Disease: Chang Gok Woo, Jooryung Huh; Journal of Pathology and Translational Medicine 2015;49(1):1-4.
DOI: https://doi.org/10.4132/jptm.2014.11.17
Published online: January 15, 2015

Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Corresponding Author: Jooryung Huh, M.D. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea Tel: +82-3010-4553, Fax: +82-472-7898, E-mail: jrhuh@amc.seoul.kr

• Received: September 5, 2014 • Revised: October 24, 2014 • Accepted: November 17, 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

11,045 Views
129 Download
13 Web of Science
12 Crossref
13 Scopus

Full Article

Download PDF

NOTES
REFERENCES

The concept of indolent T-lymphoblastic proliferation (iT-LBP) was introduced by Velankar et al. [1] as the proliferation of immature terminal deoxynucleotidyl transferase (TdT)+ T cells in extrathymic tissue without the involvement of bone marrow or peripheral blood [2]. Although the histopathologic features and the immunophenotype are similar to T-lymphoblastic lymphoma (T-LBL), iT-LBP is a benign proliferation of thymocytes that requires no treatment [1-3].

Here, we report a case of iT-LBP in association with hyaline vascular-type Castleman disease in the retroperitoneum of a Korean female. A 37-year-old woman presented with right lower quadrant pain. Abdominal computed tomography scan demonstrated a well-defined homogeneous enhancing mass in the retroperitoneum (Fig. 1A). Laparotomy was performed and the mass was resected. Grossly, the resected mass (6.3×4.8×3.1 cm) was well-demarcated, round, and rubbery-firm. The cut surface was pinkish-yellow and fleshy, exhibiting central fibrosis (Fig. 1B). Microscopically, there was a small amount of proliferation of follicles of various shapes and sizes, and expansion of the interfollicular regions with sinus obliteration (Fig. 1C). Follicles demonstrated expanded mantle zones with onion skinning, regressed germinal centers with hyperplastic follicular dendritic cells reactive for CD21, radially penetrating blood vessels, and few follicle center cells (Fig. 1D-F). Many follicles contained more than one germinal center. The interfollicular region was filled with hyperplastic high endothelial venules, hyalinizing fibrosis, and an admixture of plasma cells, eosinophils, immunoblasts, plasmacytoid dendritic cells, and lymphocytes. In addition, there were multiple nodular and diffuse areas of lymphoid cell infiltration in the interfollicular and perifollicular regions, which were composed of small- to medium-sized cells with a high nuclear/cytoplasmic ratio and slightly irregular nuclei with open chromatin and inconspicuous nucleoli (Fig. 2A, B). These cells were immunoreactive for TdT, CD3, CD4, and CD8, but negative for CD20 (Fig. 2C, D). The Ki-67 labeling index was also high (Fig. 2F). Some of the large cells in the interfollicular and perifollicular area appeared similar to dysplastic follicular dendritic cells; consequently, follicular dendritic cell sarcoma was considered. However, these cells were negative for CD21, CD23, or CD35. Systemic work-up revealed no evidence of lymphoma involvement. Polymerase chain reaction study of the T-cell receptor gamma genes using BIOMED-2 primers (Invivoscribe, San Diego, CA, USA) failed to produce evidence of monoclonal rearrangement (Fig. 2G). A provisional diagnosis of iT-LBP associated with hyaline vascular-type Castleman disease was established and the patient was observed without any further treatment. On three-month follow-up, the patient was free from disease.

A total of ten cases of iT-LBP associated with Castleman disease have been reported in the literature, with or without follicular dendritic cell tumor (FDCT) and various caricinomas. iT-LBP most commonly involves the lymph nodes, where it invades interfollicular/parafollicular areas without effacement of the architecture [2-5]. The cells are small to medium sized with blastic chromatin, and exhibit frequent mitotic figures without significant atypia or prominent nucleoli. The typical immunophenotype involves immature cortical thymocytes, expression of CD3 and TdT, coexpression of CD4 and CD8, and variable expression of other T-cell antigens (CD2, CD5, and CD7). iT-LBP may also exhibit CD10, CD99, and CD1a expression, but lacks CD34 or B-cell markers. The Ki-67 labeling index is high. The possibility of ectopic thymic tissue can be ruled out by the absence of cytokeratin-staining epithelial cells. Ohgami et al. [3] reported that the presence of TdT-positive T cells is not rare in lymph nodes with Castleman disease, FDCT, and angioimmunoblastic T-cell lymphoma, and that these cells are rarely noticeable on hematoxylin and eosin sections, although they are usually present at low density in a scattered distribution. Occasionally, they will form dense patches or tumors, and may mimic T-LBL with TdT positivity and a high Ki-67 labeling index. In contrast to T-LBL, which is a malignant monoclonal process that may involve peripheral blood, bone marrow, and the thymus, with tissue effacement, iT-LBP does not involve peripheral blood, bone marrow, or the thymus. In lymph nodes, iT-LBP does not lead to the tissue effacement typical of lymphomatous growth. A recent study indicated that iT-LBP could involve multiple lymph nodes and show partial CD33 expression [5]. In this case, immunopositivity for CD33 was also observed (Fig. 2E); however, node effacement as absent and the structure was preserved.

How immature lymphocytes localize and proliferate outside the context of thymic epithelial support remains unclear [3,4]. We suppose that immature T cells released from the thymus travel via the peripheral blood and eventually reach the lymph nodes. In a state of immune system dysfunction, these immature cells may proliferate like mature lymphocytes.

It is essential that clinicians are aware of this entity in order to avoid a misdiagnosis of T-LBL and consequent unnecessary treatment. Careful examination of morphologic features, immunochemical staining, molecular study, extent of involvement, and clinical course can contribute to the differentiation of iT-LBP from T-LBL.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Fig. 1.

Hyaline vascular-type Castleman disease. (A) Abdominal computed tomography demonstrates a well-defined homogeneous enhancing mass (arrow) in the retroperitoneum. (B) The mass exhibits a fleshy cut surface with central fibrosis. (C) Variably-sized follicles with multiple germinal centers are present. The interfollicular compartment is expanded with vascular proliferation. (D) Follicular structures appear smaller due to the regression of germinal centers. (E) Mantle zone lymphocytes have a laminated appearance, similar to onion skin. The vessel penetrating the atrophic follicle has a lollipop-like appearance. (F) Hyperplastic follicular dendritic cells are stained with CD21.

Fig. 2.

Indolent T-lymphoblastic proliferation (iTLBP). (A) Nodular and diffuse areas of monotonous lymphoid cell infiltration in the interfollicular and perifollicular regions. (B) The cells show blastic nuclei with open chromatin and inconspicuous nuclei. (C–F) Cells are immunopositive for CD3 (C), terminal deoxynucleotidyl transferase (D), and CD33 (E), and have an increased Ki-67 labeling index (F). (G) Polymerase chain reaction study of the T-cell receptor gamma genes using BIOMED-2 primers shows no evidence of monoclonality.

REFERENCES

1. Velankar MM, Nathwani BN, Schlutz MJ, et al. Indolent T-lymphoblastic proliferation: report of a case with a 16-year course without cytotoxic therapy. Am J Surg Pathol 1999; 23: 977-81. PubMed
2. Ohgami RS, Arber DA, Zehnder JL, Natkunam Y, Warnke RA. Indolent T-lymphoblastic proliferation (iT-LBP): a review of clinical and pathologic features and distinction from malignant T-lymphoblastic lymphoma. Adv Anat Pathol 2013; 20: 137-40. PubMed
3. Ohgami RS, Zhao S, Ohgami JK, et al. TdT+ T-lymphoblastic populations are increased in Castleman disease, in Castleman disease in association with follicular dendritic cell tumors, and in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 2012; 36: 1619-28. PubMed
4. Qian YW, Weissmann D, Goodell L, August D, Strair R. Indolent T-lymphoblastic proliferation in Castleman lymphadenopathy. Leuk Lymphoma 2009; 50: 306-8. PubMed
5. Ohgami RS, Sendamarai AK, Atwater SK, et al. Indolent T-lymphoblastic proliferation with disseminated multinodal involvement and partial CD33 expression. Am J Surg Pathol 2014; 38: 1298-304. PubMed

Figure & Data

References

Citations

Citations to this article as recorded by

Unicentric Castleman Disease: Updates and Novel Insights Into Spindle Cell Proliferations and Aggressive Forms of a Localized Disease
FNU Alnoor, Alexandra Rangel, Matthew Luo, Oscar Silva, Karen M. Chisholm, Dennis O'Malley, Roger Warnke, Jyoti Kumar, Robert S. Ohgami
International Journal of Laboratory Hematology.2024;[Epub] CrossRef
Indolent T-lymphoblastic proliferation with fibrolamellar hepatocellular carcinoma developed after colorectal adenocarcinoma: a case report
Wen Han, Bei Wang, Xiang Yong, Yi Zhang, Mingyu Shao, Chun Wang
Pathology and Oncology Research.2023;[Epub] CrossRef
Indolent T-lymphoblastic proliferation involving hepatocellular carcinoma—presentation in novel settings and comprehensive review of literature
Alireza Ghezavati, Christine A. Liang, Daniel Mais, Alia Nazarullah
Journal of Hematopathology.2023; 16(3): 167. CrossRef
Indolent T-lymphoblastic proliferation: a report of three cases
Zheng Yuanyuan, Xie Jianlan, Zhang Yanlin, Zhou Xiaoge
Virchows Archiv.2022; 480(5): 1121. CrossRef
Indolent T-Lymphoblastic Proliferation in Idiopathic Multicentric Castleman Disease
Nabin Raj Karki, Ahmed Samire Arfa, Natasha Savage, Abdullah Kutlar
Acta Haematologica.2022; 145(2): 214. CrossRef
Indolent T‐lymphoblastic proliferation: A systematic review of the literature analyzing the epidemiologic, clinical, and pathologic features of 45 cases
Arzu Saglam, Kunwar Singh, Sumanth Gollapudi, Jyoti Kumar, Nivaz Brar, Alexandra Butzmann, Roger Warnke, Robert S. Ohgami
International Journal of Laboratory Hematology.2022; 44(4): 700. CrossRef
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos, Ayoma D. Attygalle, Iguaracyra Barreto de Oliveira Araujo, Emilio Berti, Govind Bhagat, Anita Maria Borges, Daniel Boyer, Mariarita Calaminici, Amy Chadburn, John K. C. Chan, Wah Cheuk, Wee-Joo Chng,
Leukemia.2022; 36(7): 1720. CrossRef
T-lymphoblastic leukemia/lymphoma with interfollicular growth pattern and Castleman-like morphologic features
Weijie Li, Alexander Kats, Linda D. Cooley, Midhat S. Farooqi, Keith August
Journal of Hematopathology.2021; 14(2): 163. CrossRef
Maladie de Castleman localisée avec prolifération lymphoblastique T indolente
Bertrand Chauveau, François Le Loarer, Julia Bacci, François Baylac, Pierre Dubus, Catherine Ling, Marie Parrens
Annales de Pathologie.2019; 39(1): 29. CrossRef
Sirolimus for the Treatment of Airway Obstruction due to Indolent T-Lymphoblastic Proliferation
Eric Moughames, Ana P. Kiess, Lee M. Akst, Antoine Azar
Case Reports in Immunology.2019; 2019: 1. CrossRef
Indolent T‐lymphoblastic proliferation concomitant with acinic cell carcinoma mimicking T‐lymphoblastic lymphoma: case report and literature review
Hajime Yasuda, Miyuki Tsutsui, Yasunori Ota, Masaru Tanaka, Norio Komatsu
Histopathology.2018; 72(5): 862. CrossRef
Indolent T-lymphoblastic proliferation: a name with specific meaning—reply
Bharat N. Nathwani, Rina Kansal, Xanthi Yiakoumis, Gerassimos A. Pangalis
Human Pathology.2015; 46(11): 1786. CrossRef

PubReader
ePub Link

Cite this Article

Cite this Article: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

TdT+ T-Lymphoblastic Proliferation in Castleman Disease

J Pathol Transl Med. 2015;49(1):1-4. Published online January 15, 2015

DOI: https://doi.org/10.4132/jptm.2014.11.17

XML Download

Figure

TdT+ T-Lymphoblastic Proliferation in Castleman Disease

Fig. 1. Hyaline vascular-type Castleman disease. (A) Abdominal computed tomography demonstrates a well-defined homogeneous enhancing mass (arrow) in the retroperitoneum. (B) The mass exhibits a fleshy cut surface with central fibrosis. (C) Variably-sized follicles with multiple germinal centers are present. The interfollicular compartment is expanded with vascular proliferation. (D) Follicular structures appear smaller due to the regression of germinal centers. (E) Mantle zone lymphocytes have a laminated appearance, similar to onion skin. The vessel penetrating the atrophic follicle has a lollipop-like appearance. (F) Hyperplastic follicular dendritic cells are stained with CD21.

Fig. 2. Indolent T-lymphoblastic proliferation (iTLBP). (A) Nodular and diffuse areas of monotonous lymphoid cell infiltration in the interfollicular and perifollicular regions. (B) The cells show blastic nuclei with open chromatin and inconspicuous nuclei. (C–F) Cells are immunopositive for CD3 (C), terminal deoxynucleotidyl transferase (D), and CD33 (E), and have an increased Ki-67 labeling index (F). (G) Polymerase chain reaction study of the T-cell receptor gamma genes using BIOMED-2 primers shows no evidence of monoclonality.

Fig. 1.

Fig. 2.

TdT+ T-Lymphoblastic Proliferation in Castleman Disease